Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IONS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIonis adds former Alexion CEO Ludwig Hantson to Board, expands equity plan by 9.5M shares
Filed June 8, 2026 · Period ending June 4, 2026 · ~1 min read
Key Changes
-
medium
Ludwig N. Hantson, former Alexion CEO (2017-2021) and Baxalta CEO, joined Ionis' Board on June 4, 2026, bringing 30+ years of biopharma leadership experience to the company's governance.
Item 5.02 verify on EDGAR → -
medium
Shareholders approved expanding the 2011 Equity Incentive Plan by 9.5 million shares to 52 million total, increasing the pool for employee compensation and potential shareholder dilution.
Item 5.07 verify on EDGAR → -
low
Peter N. Reikes also joined the Board effective June 4, 2026, as previously announced in March 2026, following the company's annual meeting.
Item 5.02 verify on EDGAR → -
low
Shareholders approved adding 750,000 shares to the Employee Stock Purchase Plan and removing its termination date, making it perpetual with modest additional dilution.
Item 5.07 verify on EDGAR → -
low
Directors Spencer Berthelsen and Joan Herman were re-elected to serve until 2029, and Ernst & Young was ratified as auditor for fiscal 2026.
Item 5.07 verify on EDGAR →
Summary
Ionis Pharmaceuticals strengthened its Board of Directors by adding Ludwig Hantson, a seasoned biopharma executive who led Alexion through its acquisition by AstraZeneca. His appointment signals potential strategic shifts or M&A activity, given his track record of building and selling major biotech companies.
The timing coincides with the company's annual meeting, where shareholders also approved Peter Reikes' previously announced board seat. The annual meeting results included a significant equity plan expansion—9.5 million additional shares for employee compensation.
While this provides flexibility to attract and retain talent in a competitive biotech labor market, it represents meaningful potential dilution for existing shareholders. Combined with the 750,000 shares added to the employee stock purchase plan, Ionis is positioning itself for continued growth and hiring. Retail investors should watch for strategic announcements in coming quarters that leverage Hantson's M&A expertise. His presence may indicate Ionis is preparing for partnership deals, asset sales, or other corporate development activity. Monitor insider trading activity and any changes to the company's strategic guidance that might explain why such experienced leadership was brought aboard now.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 4, 2026, the Board of Directors (“Board”) of Ionis Pharmaceuticals, Inc. (the “Company”) appointed Ludwig N. Hantson as a member of the Company’s Board effective June 4, 2026, immediately following the Company’s 2026 Annual Meeting of Stockholders.
Ionis added Ludwig N. Hantson to its Board of Directors effective June 4, 2026. Dr. Hantson brings over 30 years of biopharmaceutical leadership experience, including serving as CEO of Alexion from 2017-2021 before its acquisition by AstraZeneca, and as CEO of Baxalta following its spin-off from Baxter Bioscience. He will receive standard non-employee director compensation including cash and automatic equity grants.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Dr. Hantson will receive the standard compensation that the Company provides to its non-employee directors, which consists of cash compensation and automatic equity grants as set forth in the Company’s Fourth Amended Non-Employee Director Compensation Policy, filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed on April 29, 2026, as amended from time to time.
Dr. Hantson will receive the company's standard non-employee director compensation package, which includes both cash payments and automatic equity grants as detailed in the Fourth Amended Non-Employee Director Compensation Policy filed with the Q1 2026 10-Q.
Event · Item 7.01 — Regulation FD Disclosure
Ionis Pharmaceuticals appointed Dr. Hantson to its Board of Directors effective June 4, 2026.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Dr. Hantson was appointed to the Company’s Board on June 4, 2026.
The company disclosed that Dr. Hantson joined the Board of Directors on June 4, 2026. This is a routine governance event announcing a new board member, disclosed via press release under Regulation FD.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Annual meeting results: directors elected, executive compensation approved, equity plan expanded by 9.5M shares, auditor ratified.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
Spencer R. Berthelsen 119,824,353 | 20,816,547 | 98,115 | 12,305,695 Joan E. Herman 135,599,646 | 5,076,895 | 62,474 | 12,305,695
Stockholders elected Spencer R. Berthelsen and Joan E. Herman as directors to serve until the 2029 Annual Meeting. Both candidates received majority support from shares voted at the meeting.
Added in current filing · verify on EDGAR →
Ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year
Stockholders ratified Ernst & Young LLP as the independent auditor for fiscal 2026 with overwhelming support (148.9 million votes for). This is a routine annual approval with no change in auditor.
Event · Item 9.01 — Financial Statements and Exhibits
Ionis filed an 8-K attaching a press release dated June 8, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1 Press Release dated June 8, 2026.
The 8-K references an attached press release dated June 8, 2026 (Exhibit 99.1). The filing body itself contains no substantive disclosure about the press release content, business event, or financial impact. Without access to Exhibit 99.1, the nature and materiality of the announcement cannot be determined from this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify